Tilray Brands, Inc.
Tilray Brands is a consumer products company headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia and Latin America. It serves beverage consumers, cannabis patients and adult-use cannabis consumers, and customers of pharmaceutical, wellness and hemp-based food products. Its four segments are Beverage, Cannabis, Distribution and Wellness. Tilray makes and sells beverages, including craft beer and spirits; cultivates, produces, distributes and sells medical and adult-use cannabis; purchases and resells pharmaceutical and wellness products; and produces and distributes hemp-based foods and other wellness products. Its brands include SweetWater, BrewDog, Breckenridge, Tilray Medical, Broken Coast, Good Supply, Redecan and Manitoba Harvest. Medical cannabis reaches patients in over 20 countries through subsidiaries and distributor agreements. In the United States, beverage products are sold through wholesalers to retail and hospitality outlets.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TLRY in the last 30 days.
See all $TLRY insider activity →Tilray Brands plans to save $20M over two years by closing breweries, reducing its U.S. brewing sites from 10 to 6, and cutting its distributor network by 9%. The company aims to focus on regional brands, national offerings, and growth categories like nonalcoholic beverages. Tilray also sold the Atwater brand and is preparing for a partnership with Carlsberg.
Tilray Brands (TLRY) plans to consolidate Canadian cannabis operations, moving production from Foss to Masson and Cayuga, aiming for $10M annual savings. The company raised FY2027 EBITDA guidance to $70M-$75M, with Masson's capacity increasing to 50 metric tonnes and EU-GMP certification expected in 2027.
Tilray Brands (TLRY) reported fiscal Q1 2027 revenue of $101.5M from beverages, up 82% YoY, and $56.1M from marijuana. European sales grew 71%, driven by acquisitions. The company is shifting focus from U.S. marijuana to global beverage and wellness markets, though it remains unprofitable.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning TLRY (Tilray Brands, Inc.). Coverage has skewed bullish: 6 bullish, 1 neutral, and 2 bearish.
Recent TLRY coverage spans financial news, earnings and mergers & acquisitions.
Cost and complexity reduction plan should support margin expansion expectations, but execution risk rises as Tilray prepares to scale for Carlsberg’s U.S. rollout.
Guidance lift and cost‑saving plan may support modest upside.
Positive earnings-driven growth in new segments.
Earnings recap shows revenue growth offset by losses and weak cannabis segment.
Analyst upgrade suggests upside potential.
AlphAI scores every news story that mentions TLRY with an AI model for sentiment and relevance, and aggregates insider trades from Tilray Brands, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tilray Brands plans to save $20M over two years by closing breweries, reducing its U.S. brewing sites from 10 to 6, and cutting its distributor network by 9%. The company aims to focus on regional brands, national offerings, and growth categories like nonalcoholic beverages. Tilray also sold the Atwater brand and is preparing for a partnership with Carlsberg.
4 min readTilray Brands (TLRY) plans to consolidate Canadian cannabis operations, moving production from Foss to Masson and Cayuga, aiming for $10M annual savings. The company raised FY2027 EBITDA guidance to $70M-$75M, with Masson's capacity increasing to 50 metric tonnes and EU-GMP certification expected in 2027.
2 min readTilray Brands (TLRY) reported fiscal Q1 2027 revenue of $101.5M from beverages, up 82% YoY, and $56.1M from marijuana. European sales grew 71%, driven by acquisitions. The company is shifting focus from U.S. marijuana to global beverage and wellness markets, though it remains unprofitable.
2 min readTilray Brands reported record Q1 2027 revenue of $257.1M, up 23% YoY, with gross profit rising 35% to $77.5M. However, cannabis revenue fell 13% to $56.1M, driven by declines in Canadian sales. Beverage revenue surged 82% to $101.5M, now 39% of total revenue. Despite improvements, Tilray posted a $40M net loss and negative free cash flow.
2 min readTilray (TLRY) is set to benefit from a partnership with Carlsberg, starting in 2027, which could increase its beverage volumes by 8% to 10%. Jefferies raised its price target to $13 from $12, citing improved capital returns and efficiency gains. Tilray aims for $20M in annual savings by 2028 and reaffirmed its FY2027 adjusted EBITDA guidance of $68M-$75M.
2 min readJefferies raised its price target on Tilray Brands (TLRY) to $13 from $12, maintaining a Reduce rating. The stock trades at $2.67, down 80% over the past year. Tilray is restructuring its U.S. brewing operations, targeting $20 million in annual savings by 2028. The company reported $257.1 million in Q1 fiscal 2027 revenue, up 23% year-over-year, but posted a net loss of $40 million.
2 min readTilray Brands Inc. (TLRY) completed the consolidation of its U.S. brewing operations, targeting $20M in annualized cost savings by fiscal 2028. The company reduced its distributor network by 9% and SKU count by 28%, reaffirming its fiscal 2027 adjusted EBITDA guidance of $68M-$75M. Tilray also announced a U.S. brewing partnership with Carlsberg, targeting 1M cases in the first year. The company's beverage platform generates approximately $500M in annual revenue.
1 min readTilray Brands announced layoffs across its portfolio, following a 70% stock price decline year-to-date. An employee attributed the cuts to panic over the stock's performance. The company has lost 97% of its value over five years, according to a Motley Fool blogger.
1 min readTilray (TLRY) has diversified into alcoholic beverages, with beer sales surpassing cannabis. The company acquired BrewDog, generating $101.5M in Q1 2027, up from $55.7M in Q1 2026. Cannabis revenue fell to $56.1M. Tilray reported record revenues, improved margins, and reduced debt, but remains unprofitable. Investors see diversification as a positive shift.
2 min readAurora Cannabis rejected Curaleaf's $5 per share takeover bid, exploring alternatives. Cronos Group acquired Dutch cannabis producer CanAdelaar for €57.5M. Tilray Medical gained Portuguese approval for in-house cannabis quality testing.
3 min read
